Tami et al showed an excellent outcome of an allogeneic HSCT in relapsed/refractory ALK+ ALCL after crizotinib with long-term remission in 5 out of 6 patients.[6] The same group and others reported favorable outcomes of allogeneic HSCT in relapsed/refractory ALCL patients suggesting a graft-versus-lymphoma (GVL) effect.[19–21] Although the optimal treatment for chemotherapy-resistant ALK+ ALCL patients has not been established yet, so far it seems to be a reasonable option to use novel agents to achieve remission and undergo allogeneic HSCT as soon as possible. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.